Should I Buy Veru Stock in 2025? South African Investor Analysis

What is Veru?

How much is the Veru stock?

The price of Veru stock is falling this week. Currently, Veru is trading at $0.5092, showing a 24-hour decrease of 3.67% and a drop of 3.96% over the past week. The company’s market capitalization stands at $77.48 million, with an average three-month daily volume of 2.06 million shares. Veru does not report a P/E ratio, as it remains unprofitable, and it offers no dividend yield. The stock’s five-year beta is -0.73, indicating lower volatility compared to the broader market. While recent clinical results bring optimism, the stock’s performance reflects the typical volatility seen in late-stage biotech investments.

Our full analysis on the Veru stock

We have conducted an intensive evaluation of Veru Inc.'s most recent financial disclosures and the stock’s trajectory over the past three years. Harnessing our proprietary analytics, which integrate macroeconomic factors, technical signals, financial metrics, and a comparative competitive analysis, we have synthesised a comprehensive outlook on this emerging biotech player. So, why might Veru stock once again become a strategic entry point into the global biopharmaceutical innovation wave in 2025?

Recent Performance and Market Context

Despite notable volatility, Veru’s share price at $0.5092 as of 30 May 2025, reflects a stock that has experienced downward pressure—down approximately 49% year-on-year and nearly 28% over six months. However, such retracements are not uncommon for late-stage clinical biotech firms—particularly those on the cusp of transformative data releases. Capitalisation stands at $77.5M, with average daily volume of 2.06 million shares, indicating continued investor engagement, even amid pronounced sector headwinds.

Recent milestones have proven catalyst-rich and supportive of future value realization:

• May 2025: Veru reported positive safety data from its Phase 2b QUALITY trial, positioning its enobosarm/semaglutide combination as a potential best-in-class therapy for GLP-1-related muscle preservation—a clinically meaningful endpoint in the obesity space.
• January 2025: The topline Phase 2b QUALITY trial results confirmed enobosarm’s benefit in preserving lean mass when added to GLP-1 therapy (notably Wegovy®), a key differentiator given growing concerns about muscle mass loss during pharmacologic weight reduction.
• The global biotech sector remains dynamic, with continued regulatory support for novel cardiometabolic and obesity-related treatments—an environment that is widely seen as supportive for advanced clinical stage innovators.

Combined, these recent developments, set against favourable broader biotech sentiment and acute demand for next-generation metabolic therapies, seem to elevate Veru’s profile as a deeply discounted opportunity with credible upside potential.

Technical Analysis

While some traditional technical indicators currently point to a cautious stance, astute investors often view technical lows and prolonged oversold conditions as advantageous entry scenarios—particularly in highly event-driven biotech equities.

• Relative Strength Index (RSI): Currently at 46.4 (neutral), not yet oversold but repositioning from previous lows, suggesting stabilization.
• MACD (12,26,9): Marginally negative at -0.002, a signal previously interpreted as bearish, but often reflecting exhausted selling pressure after pronounced drawdowns.
• Moving Averages: Clustering just below current prices on the 5-day ($0.513), 20-day ($0.532), 50-day ($0.511), and 200-day ($0.519) windows, all signalling “sell” by the letter of the algorithm. Nevertheless, confluence of price and supports—particularly near the $0.45 historic support—has provided a resilient base.
• Supports/Resistances: Key support at $0.45 (52-week low); major resistance at $1.42 (52-week high).

Though current indicators register a broadly negative momentum, the technical structure places Veru in the lower bounds of its recent trading range. For investors seeking pre-catalyst positioning, this setup appears to offer an attractive risk/reward skew, laying the groundwork for a potential bullish reversal should fundamental catalysts materialize.

Fundamental Analysis

Veru’s value rests squarely on its late-stage drug pipeline and the quality of its recent clinical data. While the company reported minimal revenues in Q2 2025—common for development-stage biotechs—it has demonstrated:

• Strong operational discipline: Q2 operational loss narrowed to $8.1M (from $8.9M a year earlier), and net loss per share improved to $0.05 vs. $0.07 in Q2 2024.
• Robust innovation engine: Enobosarm stands as the first selective androgen receptor modulator showing lean mass preservation atop GLP-1 agonist therapy, addressing a critical and rapidly-growing clinical market. Sabizabulin, targeting atherosclerotic cardiovascular inflammation, sits as a valuable second act.
• Attractive valuation: With a $77M market cap and a consensus analyst target of $4.00 (potential upside exceeding 685%), the risk-adjusted value appears skewed positively. Though price/earnings measures are not meaningful for a development-stage company, the price-to-sales and price-to-pipeline ratios as implied by analyst coverage suggest markedly depressed valuations relative to upside potential.
• Strategic strengths: Deep IP runway with patents potentially protecting assets to 2045, plus proven leadership experienced in bringing novel therapies from clinical to commercial phase.

These elements combine to make Veru an especially compelling narrative for investors seeking asymmetric opportunities—particularly those who understand and can price late-stage biotech risk.

Volume and Liquidity

Sustained daily trading volumes (2.06 million shares on average over the past three months) highlight persistent market engagement despite recent selloffs. The public float sits at 119.15M shares—offering ample liquidity for both institutional and retail investors, with the 12.14% short interest suggesting that any inflection on positive news could produce noteworthy upward momentum (“short squeeze” dynamics). This environment appears especially suitable for nimble investors seeking dynamic portfolio rotation.

Catalysts and Positive Outlook

Investors tracking the biotech space understand that valuation inflection is typically event-driven. For Veru, the near- and medium-term catalyst set aligns powerfully with this paradigm:

• Q2 and Q3 2025: Expected readouts for safety and efficacy from the QUALITY study extension, pre-Phase 3 FDA meeting, and potential fast-tracking of pivotal trials in obesity-related indications.
• Innovative pipeline evolution: New extended-release formulation of enobosarm could unlock broader label claims, enhancing addressable markets.
• First-mover advantage: Veru leads in the SARM+GLP-1 combination field, carving a proprietary niche within the obesity and metabolic treatment boom.
• ESG and social impact: Addressing cardiometabolic disease carries significant ESG credentials, a factor increasingly influential in global institutional portfolio decisions.

Furthermore, sectoral tailwinds—such as regulatory acceleration of obesity treatments, demographic increases in obesity prevalence, and healthcare system prioritisation of metabolic wellness—offer a highly supportive medium- to long-term backdrop.

Investment Strategies

Veru’s current position offers multiple attractive points for staged portfolio entry:

• Short-term: Tactical investors may look to accumulate at or just above technical support ($0.45–$0.50), anticipating pre-catalyst momentum into upcoming trial data announcements.
• Medium-term: Core positions could be built ahead of the pivotal FDA meeting in Q3 2025—the typical inflection zone for biotech valuation, historically yielding outsized returns for correctly positioned names when positive regulatory dialogue occurs.
• Long-term: For patient investors willing to navigate volatility, Veru’s intellectual-property strength through 2045, proven leadership, and advances in metabolic pipeline candidates present the hallmarks of a multiyear growth thesis with significant strategic upside, particularly as the market for solutions to metabolic and obesity-related disease expands globally—including in health-conscious African urban markets.
• For South African investors, diversification into US health innovation equities like Veru can provide portfolio resilience, global sector exposure, and participation in the frontlines of medical innovation.

Is It the Right Time to Buy Veru?

Reviewing Veru’s recent clinical achievements, solid operational management, robust liquidity, and the considerable upside projected by professional analysts, the fundamental and technical case for renewed interest appears compelling. While the company operates at the higher end of strategic risk due to clinical and funding dependency—par for the course in advanced biotechnology—its unique positioning in the growing field of obesity and cardiometabolic therapeutics sets a clear route for value realisation.

• Key strengths at a glance:
• First-mover competitive advantage in SARM + GLP-1 combinations
• Recent positive clinical data and near-term pivotal catalysts
• Clear path forward with regulatory dialogue and strong patent protection
• Attractive technical entry levels aligned with event-driven momentum

With leading-edge science, strong alignment to major healthcare trends, and a price that does not fully reflect the risk/reward profile, Veru seems to represent an excellent opportunity for investors with the appetite to participate in high-potential, event-driven healthcare stocks. As the world pivots towards personalized medical innovation, Veru’s next clinical updates could well define a new phase of robust appreciation—offering a unique chance for those well-positioned in advance of the inflection.

For discerning South African investors seeking outsized potential in the global healthtech arena, Veru’s present setup justifies a close and constructive focus as catalysts unfold in the months ahead.

How to buy Veru stock in South Africa?

Buying Veru stock online is now straightforward and secure for South African investors, provided you use a regulated broker. You generally have two main options: purchasing actual shares outright ("spot buying"), or trading via Contracts for Difference (CFDs) which lets you benefit from price changes without owning the underlying stock. Each method has its own characteristics in terms of ownership, fees, and risk. To help you choose the broker best suited to your needs, you'll find a detailed broker comparison further down this page.

Spot buying (Cash purchase)

When you buy Veru stock for cash, you become a direct shareholder in the company, with full ownership of the shares. Most brokers charge a fixed commission per order, often converted into South African rand (ZAR). For SA investors, this is usually between R100 and R200 per trade, depending on the platform, plus a small currency conversion fee if you’re buying US shares.

Example

Example: The current price of Veru is $0.5092 per share (about R9.47 at an exchange rate of 1 USD = 18.60 ZAR). With a $1,000 (roughly R18,600) stake and a brokerage fee of $5 (about R93), you could buy around 1,958 shares of Veru.
Gain scenario: If the share price rises by 10%, your holdings are now worth $1,100 (R20,460).
Result: +$100 gross gain (+10% return on your investment), excluding local taxes or minor FX adjustments.

Trading via CFD

CFD trading allows you to speculate on the price movement of Veru shares without owning the actual stock. Instead, you enter into a contract with the broker to exchange the difference in price between entry and exit. Brokers charge you via the bid/ask spread and, if you hold your position overnight, additional financing fees. CFDs also enable leverage.

Example

Example: You open a CFD on Veru with a $1,000 (R18,600) stake and 5x leverage, so your market exposure is $5,000 (R93,000).
Gain scenario: If the Veru share price climbs 8%, your position value increases by 8% × 5 = 40%.
Result: +$400 gain on your $1,000 (R18,600) bet, not including spreads and daily overnight fees.

Final advice

Before investing, always compare brokers’ fees, trading conditions, and levels of regulation. Your choice will depend on your experience, the risk you are willing to take, and whether you prefer ownership (spot) or flexibility and leverage (CFDs). For an easy overview, check out our broker comparison tool further down on this page to make the decision that best fits your investment goals.

Our 7 tips for buying Veru stock

The latest news about Veru

Veru released positive safety data from its Phase 2b QUALITY study, supporting the combined use of enobosarm and semaglutide. In May 2025, Veru announced new safety findings indicating that the enobosarm plus semaglutide combination exhibits a favorable safety profile compared to semaglutide alone. This signal is particularly constructive as it enhances confidence in the tolerability of the company's lead asset, supporting its continued clinical advancement. While Veru currently has no established operations or direct regulatory filings in South Africa, positive global safety outcomes for anti-obesity therapies—especially those relevant to widely-used medications like GLP-1 agonists—are keenly watched by investors and practitioners in South Africa, where obesity rates and demand for innovative therapies are increasing.

Veru’s financial results for Q2 2025 show reduced operating and net losses, indicating improved cost management during continued R&D investment. For the quarter ending March 31, 2025, the company reported an operating loss of $8.1M and a net loss of $7.9M, both lower than the previous year’s comparable period. Although revenue remains minimal—normal for a late-stage biotech in clinical development—Veru’s focus on controlling burn rate is notable and aligns with best practices for pre-commercial biopharmas. For South African analysts, the ability of biotech firms to sustain pipeline progression within financial constraints is a crucial metric, particularly as local investors seek exposure to global healthcare innovation with manageable cash flow risks.

Consensus analyst opinion remains strongly positive, with a high price target relative to current levels. According to the latest available data, analysts continue to rate Veru as a "Buy," with a mean 12-month price target of $4.00 per share, implying substantial upside from the current $0.50 share price. While the stock’s low valuation and high-risk profile are typical within its peer group, this level of potential return stands out. Institutional and sophisticated investors in South Africa often monitor such high-potential U.S. biotech situations, particularly where global clinical data could support future partnerships, licensing, or market access discussions in emerging markets.

Recent clinical results position Veru for regulatory advancement, with confirmed plans for a Phase 3 program and upcoming FDA discussions. Following the topline efficacy results and new safety data, Veru is preparing for an end-of-Phase 2 meeting with the FDA anticipated in Q3 2025, with Phase 3 development on the horizon. The company also continues to develop a novel modified-release formulation of enobosarm. These advancements are material de-risking events that could catalyze further re-rating of the stock. For South African market participants, evidence of regulatory momentum and late-stage pipeline focus increases the attractiveness of tracking Veru for potential inclusion in healthcare innovation strategies or indices that favor international clinical-stage companies.

The innovative mechanism of Veru’s lead drug addresses key gaps in the GLP-1 obesity treatment landscape, relevant given South Africa’s high obesity prevalence and therapeutic needs. Enobosarm’s profile as the first agent to robustly demonstrate muscle mass preservation in combination with GLP-1 receptor agonists resonates in the context of South Africa’s rising rates of obesity and metabolic syndrome, where muscle atrophy during weight loss is a concern. With global GLP-1 access expanding—including in private health and large public sector initiatives in South Africa—the availability of safe adjunct therapies with meaningful clinical endpoints offers significant value. While local regulatory approval and distribution remain longer-term considerations, the innovative nature of Veru’s pipeline is aligned with the interests of South African healthcare investors and practitioners seeking international best-in-class solutions.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.